Survodutide Drug Asset Due Diligence Report 2026

This Survodutide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Survodutide can convert its Synthetic peptide profile and GCGR x GLP-1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Survodutide (query alias: survodutide)
Modality / target	Synthetic peptide; GCGR x GLP-1R; GCGR agonists, GLP-1R agonists
Highest global status	Phase 3
Originator	Zealand Pharma A/S
Active developers	Boehringer Ingelheim (China) Investment Co., Ltd., Boehringer Ingelheim GmbH, Boehringer Ingelheim International GmbH

The MCP disease footprint includes Liver Cirrhosis, Cicatrix, Fibrosis, Liver. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07206290	Phase 2	Not yet recruiting	120	Change in first morning void UACR
NCT07221591	Phase 1	Active, not recruiting	100	Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
NCT07413913	Phase 1	Completed	56	Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Survodutide Once Weekly for the Treatment of Adults with Obesity

Phase 3; n=725; evaluation: Positive. Reported fields: Body weight(76-week) = -13.0 % ( -14.4 to -11.6); Body weight(76-week) = -12.2 % ( -13.6 to -10.8); Body weight(76-week) = -5.4 % ( -6.9 to -4.0)

Multicenter, Double-blind, Parallel-group, Randomized, 48 Weeks, Dose-ranging, Placebo-controlled Phase II Trial to Evaluate Efficacy, Safety and Tolerability of Multiple Subcutaneous (s.c.) Doses of BI 456906 in Patients With Non-alcoholic Steatohepatitis (NASH) and Fibrosis.

Phase 2; n=295; evaluation: not stated. Reported fields: Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment: Odds Ratio (OR) = 3.47(95% CI, 1.66 - 7.25), P-Value = 0.0010; Odds Ratio (OR) = 9.52(95% CI, 4.35 - 20.85), P-Value = <0.0001; Odds Ratio (OR) = 7.07(95% CI, 3.10 - 16.16), P-Value = <.0001; P-Value = <0.0001; P-Value = <0.0001; P-Value = 0.0008; P-Value = <0.0001; P-Value = <0.0001; P-Value = <0.0001; Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment: Odds Ratio (OR) = 3.47(95% CI, 1.66 - 7.25), P-Value = 0.0010; Odds Ratio (OR) = 9.52(95% CI, 4.35 - 20.85), P-Value = <0.0001; Odds Ratio (OR) = 7.07(95% CI, 3.10 - 16.16), P-Value = <.0001; P-Value = <0.0001; P-Value = <0.0001; P-Value = 0.0008; P-Value = <0.0001; P-Value = <0.0001; P-Value = <0.0001; Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance Treatment = 55.8 Percentage of participants

Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial

Phase 2; n=387; evaluation: Positive. Reported fields: WC = 16.6 cm

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Survodutide addresses Liver Cirrhosis, Cicatrix, Fibrosis, Liver. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2011-06-16	Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity	Phase 1	US$413.6M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “GLP-1 receptor agonist compounds for treating a proliferative synovial disorder”. The milestone feed surfaced a patent-application signal described as “Composition comprising a GLP1r agonist and engineered extracellular vesicles comprising adiponectin, and uses thereof”. The milestone feed surfaced a patent-application signal described as “Controlled-release formulations of GLP-1 receptor agonists utilizing self-assembling peptides (SAPS)”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO